Intrexon Corp. (XON) Upgraded to Hold at Zacks Investment Research
Intrexon Corp. (NYSE:XON) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Intrexon is a leader in the synthetic biology field, with its focus on the broad delivery of bioindustrial engineering to design and create solutions across five key sectors – health, food, energy, environment and consumer. We believe that the company’s core area – synthetic biology – holds huge potential. Intrexon’s expanding portfolio of technologies has enabled the company to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are positive on the company’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures (JV). Estimates are mostly stable ahead of Q3 results. However, Intrexon depends largely on ECCs and license and collaboration agreements for revenues. Any unfavorable outcome from any of the development programs could become a major setback for the company and dent its operating results and prospects.”
XON has been the topic of a number of other research reports. Wunderlich reaffirmed a “buy” rating and set a $50.00 price target on shares of Intrexon Corp. in a report on Thursday, July 7th. Stifel Nicolaus reaffirmed a “buy” rating and set a $57.00 price target on shares of Intrexon Corp. in a report on Wednesday, June 29th. JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research note on Sunday, July 17th. Vetr upgraded shares of Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price objective on the stock in a research note on Wednesday, August 3rd. Finally, Griffin Securities reiterated a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corp. in a research note on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $41.71.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/intrexon-corp-xon-upgraded-to-hold-at-zacks-investment-research.html
Shares of Intrexon Corp. (NYSE:XON) traded down 0.870% during trading on Monday, reaching $26.448. 495,535 shares of the company traded hands. The company’s 50-day moving average price is $27.37 and its 200-day moving average price is $27.86. The company’s market capitalization is $3.13 billion. Intrexon Corp. has a 52 week low of $18.52 and a 52 week high of $43.76.
Intrexon Corp. (NYSE:XON) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.16. The company had revenue of $52.50 million for the quarter, compared to analysts’ expectations of $53.78 million. Intrexon Corp. had a negative net margin of 96.65% and a negative return on equity of 19.00%. The business’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.37) EPS. Equities research analysts forecast that Intrexon Corp. will post ($1.36) EPS for the current fiscal year.
In other news, SVP Nir Nimrodi bought 4,000 shares of the firm’s stock in a transaction on Monday, August 29th. The shares were bought at an average price of $26.12 per share, for a total transaction of $104,480.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 55.10% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Aperio Group LLC purchased a new stake in Intrexon Corp. during the first quarter worth approximately $299,000. TIAA CREF Investment Management LLC boosted its stake in Intrexon Corp. by 2.3% in the first quarter. TIAA CREF Investment Management LLC now owns 141,930 shares of the company’s stock worth $4,810,000 after buying an additional 3,189 shares during the last quarter. Teachers Advisors Inc. boosted its stake in Intrexon Corp. by 8.9% in the first quarter. Teachers Advisors Inc. now owns 37,984 shares of the company’s stock worth $1,287,000 after buying an additional 3,104 shares during the last quarter. BlackRock Inc. boosted its stake in Intrexon Corp. by 321.0% in the first quarter. BlackRock Inc. now owns 5,780 shares of the company’s stock worth $195,000 after buying an additional 4,407 shares during the last quarter. Finally, BlackRock Group LTD boosted its stake in Intrexon Corp. by 9.1% in the first quarter. BlackRock Group LTD now owns 33,713 shares of the company’s stock worth $1,143,000 after buying an additional 2,816 shares during the last quarter. Institutional investors own 84.10% of the company’s stock.
About Intrexon Corp.
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.